PHAR
Pharming GroupPHAR
PHAR
About: Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Employees: 404
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% less ownership
Funds ownership: 0.01% [Q4 2024] → 0.01% (-0%) [Q1 2025]
17% less capital invested
Capital invested by funds: $514K [Q4 2024] → $427K (-$87.6K) [Q1 2025]
40% less funds holding
Funds holding: 5 [Q4 2024] → 3 (-2) [Q1 2025]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$37
244%
upside
Avg. target
$38
253%
upside
High target
$39
263%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 244%upside $37 | Buy Reiterated | 21 Mar 2025 |
Oppenheimer Michael Carrier | 263%upside $39 | Outperform Maintained | 14 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 days ago
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
Neutral
GlobeNewsWire
2 weeks ago
Pharming Group to participate in June investor conferences
Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of June:
Neutral
Seeking Alpha
1 month ago
Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Joe Pantginis - H.C.
Neutral
GlobeNewsWire
1 month ago
Pharming Group reports first quarter 2025 financial results and provides business update
Leiden, the Netherlands, May 8, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary unaudited financial report for the three months ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company's 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company's website under Investors/Shareholder Meetings.
Neutral
GlobeNewsWire
1 month ago
Pharming Group to report first quarter 2025 financial results on May 8
Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025.
Neutral
GlobeNewsWire
1 month ago
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Neutral
GlobeNewsWire
2 months ago
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website.
Neutral
GlobeNewsWire
2 months ago
Pharming Group to participate in April investor conferences
Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of April:
Neutral
Seeking Alpha
3 months ago
Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Fabrice Chouraqui - CEO Stephen Toor - CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Ben Jackson – Jefferies Alistair Campbell - RBC Capital Markets Joe Pantginis - H.C.
Charts implemented using Lightweight Charts™